A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS) Clinical Trial

Official title:

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00445172
• Other study ID #: E0302-J081-762
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: February 2008
• Est. completion date: March 31, 2017

Study information

• Verified date: August 2017
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 135
• Est. completion date: March 31, 2017
• Est. primary completion date: March 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Patients who have completed Phase II/III study of E0302 (E0302-J081-761, hereafter referred to as Study 761) except for those patients who discontinued the treatment of Study 761. Completed patients are defined as those who completed the treatment period of Study 761, those on 24-hour use of non-invasive positive pressure ventilation (NIPPV), or those who eventually resulted in the use of NIPPV.

2. Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.

Exclusion Criteria:

1. Patients with cognitive impairment.

2. Pregnant women or women who may have a possibility of becoming pregnant.

3. Patients or their partners who are not willing to use reliable contraception.

4. Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to "Ministry of Health, Labor and Welfare (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3." However, an event due to the primary disease will be precluded).

5. Patients with malignant tumor.

6. Patients who participated in another clinical study after the completion of Study 761.

7. Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock).

8. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Amyotrophic Lateral Sclerosis (ALS)
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• E0302 (mecobalamin)
Intramuscular injection, mecobalamin twice a week.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events as a Measure of safety		Every 3 months
Secondary	Survival rate		Every 3 months
Secondary	Functional rating scale		Every 3 months
Secondary	Percent-predicted forced vital capacity (%FVC.)		Every 3 months